Analyst Thursdays: Benjamin Burnett discusses names and topics on Stifel's 2024 'Key Controversies List'

blonca9
Jan 4, 2024
1 min read

Stifel's Benjamin Burnett gives his take on biotech and discusses Iovance, Cabaletta, Arcellx, Revolution Medicines, Fate, CRISPR Therapeutics, and Disc Medicine.

Recent Posts

See All

RBC Global Healthcare Conference: Desk Strategist Chris McCarthy shares how institutional investors have been affected by policy and macro factors, and how they have been positioning around catalysts

RBC Global Healthcare Conference: Senior Biotech Analyst Luca Issi shares his thoughts on the current state of gene and cell therapy

RBC Global Healthcare Conference: RBC's Brian Abrahams shares his take on biotech and offers advice for companies on how to navigate these times of change

Analyst Thursdays: Benjamin Burnett discusses names and topics on Stifel's 2024 'Key Controversies List'

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight